Insight Partners, a global investment company, led a $50m Series B round in Unlearn, a developer of the first machine-learning technology that creates digital twins of patients in clinical trials, with participation from Radical Ventures, 8VC, DCVC, and Mubadala Capital Ventures. “Unlearn continues to make rapid progress as we expand our work with global biopharmaceutical companies and advance productive conversations with global regulatory authorities who are committed to supporting innovation in clinical trials. This new financing is validation of our expanding footprint in clinical trials. We are proud to have the support of this world-class syndicate of investors and welcome both Insight Partners and Radical Ventures to the Unlearn team,” Charles Fisher, Unlearn Founder and CEO.